Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.
Actively Recruiting
Researchers are conducting a long-term extension study to evaluate the safety, tolerability, and effectiveness of ORX750 in adults aged 18 to 65 years who have narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia. This study follows participants who completed a previous ORX750 clinical trial and focuses on providing ongoing information about the treatment over an extended period. Participants will receive oral ORX750 in an open-label format, grouped by their specific diagnosis narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia. The study does not involve randomization or blinding, allowing all participants to know they are receiving the study drug. The treatment and monitoring periods include assessments up to about 70 days for safety and roughly 63 days for measures of drug concentration and wakefulness. During the study, participants will undergo frequent evaluations including monitoring for adverse events, laboratory tests, vital signs, ECGs, and assessments for suicidal thoughts or behaviors. They will also complete tests measuring wakefulness and sleepiness levels. This ongoing observation aims to ensure the treatments safety and to understand its effects over time, with participant involvement lasting through the entire study period.
Actively Recruiting
Researchers are evaluating the long-term safety, tolerability, and lasting effects of ALKS 2680 tablets in adults with Narcolepsy Type 1, Narcolepsy Type 2, or Idiopathic Hypersomnia. This study involves participants who have completed earlier ALKS 2680 parent studies and aims to continue monitoring treatment impact over an extended period. Participants receive oral ALKS 2680 tablets once daily at doses ranging from 4 mg to 18 mg. The study follows a non-randomized, open-label design, and includes three groups based on the specific condition Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia. The treatment duration extends up to 248 weeks, allowing long-term observation of the medications effects. During the study, participants undergo regular assessments including monitoring for adverse events, changes in sleep latency using the Maintenance of Wakefulness Test, sleepiness severity via the Epworth Sleepiness Scale, weekly cataplexy rate, and idiopathic hypersomnia severity. Safety and treatment effects are tracked throughout the study period, which may last up to nearly five years, ensuring ongoing evaluation of participant health and treatment durability.
Actively Recruiting
Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of expanded dosing schedules of Xywav in adults with narcolepsy or idiopathic hypersomnia IH. This Phase 3 trial compares different dosing regimens of Xywav to placebo to better understand treatment options for these sleep disorders. The study is sponsored by Jazz Pharmaceuticals and focuses on adult participants aged 18 to 75 years. Participants will undergo three treatment phases an open-label titration and optimization period OL-TOP lasting up to 12 weeks to establish a stable dose of Xywav, followed by a stable dose period SDP of 2 weeks where they continue the stable dose. Finally, participants enter a double-blind randomized withdrawal period DBRWP for 2 weeks, where they are randomly assigned to continue their Xywav dose or switch to placebo. The expanded dosing regimens include once-nightly or twice-nightly doses based on prior treatment and investigator decision. Total treatment duration can be up to 16 weeks. During the trial, participants will be regularly assessed for sleepiness using the Epworth Sleepiness Scale and other sleep-related measures. Researchers will also monitor cataplexy frequency, sleep quality, and symptom severity through questionnaires and clinical evaluations. Safety will be tracked by recording adverse events. Participants will be closely followed throughout the treatment periods, with outcome measures taken at the end of each phase to evaluate the effects of the expanded dosing regimens.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effects of ORX750 in adults with Narcolepsy Type 1 NT1, Narcolepsy Type 2 NT2, and Idiopathic Hypersomnia IH. These rare conditions cause excessive daytime sleepiness and affect daily activities such as school, work, and driving. The study aims to understand how ORX750, which mimics the brain protein orexin that helps maintain wakefulness, impacts sleepiness and other symptoms in these conditions. Participants will receive either ORX750 capsules or matching placebo capsules in a randomized, double-blind setup. The study assesses multiple groups those with NT1, NT2, and IH. The treatment and monitoring will occur over a period of up to 35 days, including evaluation of plasma drug levels and sleepiness measures. During the study, participants will undergo safety assessments including monitoring for adverse events, laboratory tests, vital signs, ECGs, and suicidal ideation screening up to day 35. Researchers will also measure sleepiness using the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale. The total study duration for each participant is about five weeks, with careful observation of how the body processes ORX750 and its effects on daytime alertness.
Actively Recruiting
Idiopathic Hypersomnia IH is a condition where adults feel extremely sleepy during the day, especially in the morning, even after sleeping a lot at night. This condition can cause difficulty waking up, trouble focusing, and symptoms like dizziness. Researchers are studying TAK-360, a drug that acts like orexin, a brain chemical that helps keep people awake. The study aims to understand how safe and tolerable TAK-360 is for adults with IH and to find the right dose to help with wakefulness. Participants in the study will be randomly assigned to receive either TAK-360 tablets or placebo tablets that look the same but contain no active medicine. Both treatments will be taken orally for 4 weeks. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo, to fairly evaluate the effects of TAK-360. During the study, participants will be monitored for safety and side effects up to 8 weeks. Researchers will measure changes in daytime sleepiness using the Epworth Sleepiness Scale and symptoms using the Idiopathic Hypersomnia Severity Scale at the start and after 4 weeks. The trial will also track any treatment-emergent adverse events. The total participation time may include screening, treatment, and follow-up assessments over several weeks.
Actively Recruiting
Narcolepsy Type 2 NT2 is a lifelong condition causing excessive daytime sleepiness and difficulty staying awake, which can disrupt daily activities and quality of life. Researchers are studying TAK-360, a drug that acts like the brain chemical orexin, to evaluate its safety, tolerability, and potential to help adults with NT2 stay awake. This Phase 2 trial also aims to determine the right dosage of TAK-360. Participants will be randomly assigned to receive either TAK-360 tablets or matching placebo tablets orally for 4 weeks. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. Throughout the study, participants will be monitored for treatment-emergent adverse events up to 15 weeks. Researchers will measure changes from baseline to week 4 in sleepiness using the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test. This helps evaluate how well TAK-360 helps participants stay awake and alert during the day.
Actively Recruiting
Central hypersomnia conditions, including narcolepsy types 1 and 2 and idiopathic hypersomnia, cause excessive daytime sleepiness due to the brains difficulty in keeping a person awake. Narcolepsy type 1 includes sudden muscle weakness called cataplexy, while type 2 does not. Idiopathic hypersomnia causes extreme sleepiness without refreshment from naps. This long-term extension study evaluates how well participants tolerate and how safe the study drug TAK-360 is when taken over an extended period. Participants who finished earlier TAK-360 studies can join this trial. Everyone will receive TAK-360 tablets, either continuing their previous dose or switching to the closest available dose. Those who had placebo in prior studies will receive TAK-360 now. Placebo tablets may be given during this study to keep dosing blind but only as needed. Treatment will last for up to approximately five years. Participants will visit the clinic multiple times throughout the study for assessments. Researchers will monitor safety by tracking adverse events and measure sleepiness, sleep latency, and narcolepsy symptoms using various scales and participant diaries. These evaluations will continue over the study duration to understand long-term effects of TAK-360 in central hypersomnia conditions.
Actively Recruiting
Researchers are evaluating the safety and tolerability of TAK-861 in people with narcolepsy type 1 NT1. This study focuses on participants who have already been exposed to TAK-861 doses in previous clinical trials. The goal is to monitor how TAK-861 affects symptoms such as excessive daytime sleepiness and cataplexy episodes over a long period. All participants in this trial will receive TAK-861 tablets. Those who previously received a placebo will be randomly assigned to one of the TAK-861 dose groups. The study is a long-term extension conducted worldwide and is expected to last approximately five years or until the product is approved or the study is stopped. Participants may switch doses as needed and will attend multiple clinic visits, some of which can be done at home. Throughout the trial, participants will be regularly assessed for safety by tracking any treatment-emergent adverse events. Researchers will also measure changes in sleep latency, sleepiness scores, and cataplexy rates compared to baseline data from earlier trials. Follow-up assessments will take place four weeks after the final dose to monitor ongoing effects and ensure participant safety.
1-10 of 14
1